{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T07:32:13Z","timestamp":1749195133069,"version":"3.32.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Carolinas Muscular Dystrophy Research Endowment, Atrium Health"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Dystroglycanopathy is characterized by reduced or lack of matriglycan, a cellular receptor for laminin as well as other extracellular matrix proteins. Recent studies have delineated the glycan chain structure of the matriglycan and the pathway with key components identified. FKRP functions as ribitol-5-phosphate transferase with CDP-ribitol as the substrate for the extension of the glycan chain. Supplement of ribitol and ribose have been reported to increase the levels of CDP-ribitol in both cells and in muscles in vivo. Clinical trials with both ribitol and ribose have been reported for treating LGMD2I caused by mutations in the FKRP gene. Here we compared the comprehensive metabolite profiles of the skeletal muscle between ribitol-treated and ribose-treated FKRP mutant mice. The closely related pentose and pentitol show clearly differential impacts on metabolisms despite their similarity in enhancing the levels of CDP-ribitol and matriglycan synthesis. Supplement of ribitol changes lysophospholipid sub-pathway metabolite profiling with a trend towards normalization as reported in the muscle after AAV9-FKRP gene therapy. Ribose treatment significantly increases level of ribonate and elevates levels of advanced glycation end products. Further analysis is required to determine which metabolite is prudent to use for long-term daily treatment of dystroglycanopathies.<\/jats:p>","DOI":"10.1038\/s41598-024-83661-4","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T14:24:27Z","timestamp":1736346267000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Ribitol and ribose treatments differentially affect metabolism of muscle tissue in FKRP mutant mice"],"prefix":"10.1038","volume":"15","author":[{"given":"Marcela P.","family":"Cataldi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi L.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,8]]},"reference":[{"key":"83661_CR1","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1093\/glycob\/cwv021","volume":"25","author":"T Yoshida-Moriguchi","year":"2015","unstructured":"Yoshida-Moriguchi, T. & Campbell, K. P. Matriglycan: a novel polysaccharide that links dystroglycan to the basement membrane. Glycobiology 25, 702\u2013713 (2015).","journal-title":"Glycobiology"},{"key":"83661_CR2","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1093\/glycob\/cwx062","volume":"27","author":"MO Sheikh","year":"2017","unstructured":"Sheikh, M. O., Halmo, S. M. & Wells, L. Recent advancements in understanding mammalian O-mannosylation. Glycobiology 27, 806\u2013819 (2017).","journal-title":"Glycobiology"},{"key":"83661_CR3","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/0092-8674(94)90051-5","volume":"77","author":"JT Campanelli","year":"1994","unstructured":"Campanelli, J. T., Roberds, S. L., Campbell, K. P. & Scheller, R. H. A role for dystrophin-associated glycoproteins and utrophin in agrin-induced AChR clustering. Cell 77, 663\u2013674 (1994).","journal-title":"Cell"},{"key":"83661_CR4","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/0092-8674(94)90052-3","volume":"77","author":"SH Gee","year":"1994","unstructured":"Gee, S. H., Montanaro, F., Lindenbaum, M. H. & Carbonetto, S. Dystroglycan-alpha, a dystrophin-associated glycoprotein, is a functional agrin receptor. Cell 77, 675\u2013686 (1994).","journal-title":"Cell"},{"issue":"Pt 2","key":"83661_CR5","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1242\/jcs.112.2.209","volume":"112","author":"SC Brown","year":"1999","unstructured":"Brown, S. C. et al. Dystrophic phenotype induced in vitro by antibody blockade of muscle alpha-dystroglycan-laminin interaction. J. Cell. Sci. 112 (Pt 2), 209\u2013216 (1999).","journal-title":"J. Cell. Sci."},{"key":"83661_CR6","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1093\/emboj\/18.4.863","volume":"18","author":"JF Talts","year":"1999","unstructured":"Talts, J. F., Andac, Z., Gohring, W., Brancaccio, A. & Timpl, R. Binding of the G domains of laminin alpha1 and alpha2 chains and perlecan to heparin, sulfatides, alpha-dystroglycan and several extracellular matrix proteins. EMBO J. 18, 863\u2013870 (1999).","journal-title":"EMBO J."},{"key":"83661_CR7","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1083\/jcb.200105003","volume":"154","author":"S Sugita","year":"2001","unstructured":"Sugita, S. et al. A stoichiometric complex of neurexins and dystroglycan in brain. J. Cell. Biol. 154, 435\u2013445 (2001).","journal-title":"J. Cell. Biol."},{"key":"83661_CR8","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1038\/nn.2160","volume":"11","author":"S Sato","year":"2008","unstructured":"Sato, S. et al. Pikachurin, a dystroglycan ligand, is essential for photoreceptor ribbon synapse formation. Nat. Neurosci. 11, 923\u2013931 (2008).","journal-title":"Nat. Neurosci."},{"key":"83661_CR9","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/nchembio.2146","volume":"12","author":"DC Briggs","year":"2016","unstructured":"Briggs, D. C. et al. Structural basis of laminin binding to the LARGE glycans on dystroglycan. Nat. Chem. Biol. 12, 810\u2013814 (2016).","journal-title":"Nat. Chem. Biol."},{"key":"83661_CR10","doi-asserted-by":"publisher","first-page":"10992","DOI":"10.1073\/pnas.1605265113","volume":"113","author":"EP Rader","year":"2016","unstructured":"Rader, E. P. et al. Role of dystroglycan in limiting contraction-induced injury to the sarcomeric cytoskeleton of mature skeletal muscle. Proc. Natl. Acad. Sci. USA 113, 10992\u201310997 (2016).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"83661_CR11","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1086\/324412","volume":"69","author":"M Brockington","year":"2001","unstructured":"Brockington, M. et al. Mutations in the fukutin-related protein gene (FKRP) cause a form of congenital muscular dystrophy with secondary laminin alpha2 deficiency and abnormal glycosylation of alpha-dystroglycan. Am. J. Hum. Genet. 69, 1198\u20131209 (2001).","journal-title":"Am. J. Hum. Genet."},{"key":"83661_CR12","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1136\/jmg.2003.013870","volume":"41","author":"D de Beltran-Valero","year":"2004","unstructured":"de Beltran-Valero, D. et al. Mutations in the FKRP gene can cause muscle-eye-brain disease and Walker-Warburg syndrome. J. Med. Genet. 41, e61 (2004).","journal-title":"J. Med. Genet."},{"key":"83661_CR13","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1016\/j.celrep.2016.02.017","volume":"14","author":"M Kanagawa","year":"2016","unstructured":"Kanagawa, M. et al. Identification of a post-translational modification with ribitol-phosphate and its defect in muscular dystrophy. Cell. Rep. 14, 2209\u20132223 (2016).","journal-title":"Cell. Rep."},{"key":"83661_CR14","doi-asserted-by":"crossref","unstructured":"Praissman, J. L. et al. The functional O-mannose glycan on alpha-dystroglycan contains a phospho-ribitol primed for matriglycan addition. Elife 5 (2016).","DOI":"10.7554\/eLife.14473"},{"key":"83661_CR15","doi-asserted-by":"publisher","first-page":"11534","DOI":"10.1038\/ncomms11534","volume":"7","author":"I Gerin","year":"2016","unstructured":"Gerin, I. et al. ISPD produces CDP-ribitol used by FKTN and FKRP to transfer ribitol phosphate onto alpha-dystroglycan. Nat. Commun. 7, 11534 (2016).","journal-title":"Nat. Commun."},{"key":"83661_CR16","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1073\/pnas.0307228101","volume":"101","author":"H Manya","year":"2004","unstructured":"Manya, H. et al. Demonstration of mammalian protein O-mannosyltransferase activity: coexpression of POMT1 and POMT2 required for enzymatic activity. Proc. Natl. Acad. Sci. USA  101, 500\u2013505 (2004).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"83661_CR17","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1126\/science.1239951","volume":"341","author":"T Yoshida-Moriguchi","year":"2013","unstructured":"Yoshida-Moriguchi, T. et al. SGK196 is a glycosylation-specific O-mannose kinase required for dystroglycan function. Science 341, 896\u2013899 (2013).","journal-title":"Science"},{"key":"83661_CR18","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.ajhg.2012.07.009","volume":"91","author":"MC Manzini","year":"2012","unstructured":"Manzini, M. C. et al. Exome sequencing and functional validation in zebrafish identify GTDC2 mutations as a cause of Walker-Warburg syndrome. Am. J. Hum. Genet. 91, 541\u2013547 (2012).","journal-title":"Am. J. Hum. Genet."},{"key":"83661_CR19","doi-asserted-by":"publisher","first-page":"14087","DOI":"10.1074\/jbc.M310614200","volume":"279","author":"T Hiruma","year":"2004","unstructured":"Hiruma, T. et al. A novel human beta1,3-N-acetylgalactosaminyltransferase that synthesizes a unique carbohydrate structure, GalNAcbeta1-3GlcNAc. J. Biol. Chem. 279, 14087\u201314095 (2004).","journal-title":"J. Biol. Chem."},{"key":"83661_CR20","doi-asserted-by":"publisher","first-page":"24618","DOI":"10.1074\/jbc.M116.751917","volume":"291","author":"H Manya","year":"2016","unstructured":"Manya, H. et al. The muscular dystrophy gene TMEM5 encodes a Ribitol beta1,4-Xylosyltransferase required for the functional glycosylation of dystroglycan. J. Biol. Chem. 291, 24618\u201324627 (2016).","journal-title":"J. Biol. Chem."},{"key":"83661_CR21","doi-asserted-by":"crossref","unstructured":"Willer, T. et al. The glucuronyltransferase B4GAT1 is required for initiation of LARGE-mediated alpha-dystroglycan functional glycosylation. Elife 3 (2014).","DOI":"10.7554\/eLife.03941"},{"key":"83661_CR22","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1126\/science.1214115","volume":"335","author":"K Inamori","year":"2012","unstructured":"Inamori, K. et al. Dystroglycan function requires xylosyl- and glucuronyltransferase activities of LARGE. Science 335, 93\u201396 (2012).","journal-title":"Science"},{"key":"83661_CR23","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/j.chembiol.2015.10.014","volume":"22","author":"M Riemersma","year":"2015","unstructured":"Riemersma, M. et al. Human ISPD is a cytidyltransferase required for dystroglycan O-Mannosylation. Chem. Biol. 22, 1643\u20131652 (2015).","journal-title":"Chem. Biol."},{"key":"83661_CR24","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.omtn.2018.02.008","volume":"11","author":"JD Tucker","year":"2018","unstructured":"Tucker, J. D., Lu, P. J., Xiao, X. & Lu, Q. L. Overexpression of mutant FKRP restores functional glycosylation and improves dystrophic phenotype in FKRP mutant mice. Mol. Ther. Nucleic Acids  11, 216\u2013227 (2018).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"83661_CR25","doi-asserted-by":"publisher","first-page":"3448","DOI":"10.1038\/s41467-018-05990-z","volume":"9","author":"MP Cataldi","year":"2018","unstructured":"Cataldi, M. P., Lu, P., Blaeser, A. & Lu, Q. L. Ribitol restores functionally glycosylated alpha-dystroglycan and improves muscle function in dystrophic FKRP-mutant mice. Nat. Commun. 9, 3448 (2018).","journal-title":"Nat. Commun."},{"key":"83661_CR26","first-page":"171","volume":"65","author":"RMJ Thewissen","year":"2024","unstructured":"Thewissen, R. M. J. et al. Oral ribose supplementation in dystroglycanopathy: a single case study. JIMD Rep. 65, 171\u2013181 (2024).","journal-title":"JIMD Rep."},{"key":"83661_CR27","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s10719-014-9518-x","volume":"31","author":"G Ravi","year":"2014","unstructured":"Ravi, G. & Venkatesh, Y. P. Recognition of riboflavin and the capsular polysaccharide of Haemophilus influenzae type b by antibodies generated to the haptenic epitope D-ribitol. Glycoconj. J. 31, 247\u2013258 (2014).","journal-title":"Glycoconj. J."},{"key":"83661_CR28","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1471-2121-10-10","volume":"10","author":"Y Wei","year":"2009","unstructured":"Wei, Y., Chen, L., Chen, J., Ge, L. & He, R. Q. Rapid glycation with D-ribose induces globular amyloid-like aggregations of BSA with high cytotoxicity to SH-SY5Y cells. BMC Cell. Biol. 10, 10 (2009).","journal-title":"BMC Cell. Biol."},{"key":"83661_CR29","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.bbagen.2012.01.005","volume":"1820","author":"Y Wei","year":"2012","unstructured":"Wei, Y. et al. D-ribose in glycation and protein aggregation. Biochim. Biophys. Acta  1820, 488\u2013494 (2012).","journal-title":"Biochim. Biophys. Acta"},{"key":"83661_CR30","doi-asserted-by":"publisher","first-page":"e0278711","DOI":"10.1371\/journal.pone.0278711","volume":"17","author":"JD Tucker","year":"2022","unstructured":"Tucker, J. D., Doddapaneni, R., Lu, P. J. & Lu, Q. L. Ribitol alters multiple metabolic pathways of central carbon metabolism with enhanced glycolysis: a metabolomics and transcriptomics profiling of breast cancer. PLoS One  17, e0278711 (2022).","journal-title":"PLoS One"},{"key":"83661_CR31","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.omtm.2018.10.004","volume":"11","author":"CH Vannoy","year":"2018","unstructured":"Vannoy, C. H., Leroy, V. & Lu, Q. L. Dose-dependent effects of FKRP gene-replacement therapy on functional rescue and longevity in dystrophic Mice. Mol. Ther. Methods Clin. Dev. 11, 106\u2013120 (2018).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"83661_CR32","doi-asserted-by":"publisher","first-page":"10070","DOI":"10.1038\/s41598-019-46431-1","volume":"9","author":"CH Vannoy","year":"2019","unstructured":"Vannoy, C. H., Leroy, V., Broniowska, K. & Lu, Q. L. Metabolomics analysis of skeletal muscles from FKRP-deficient mice indicates improvement after gene replacement therapy. Sci. Rep. 9, 10070 (2019).","journal-title":"Sci. Rep."},{"key":"83661_CR33","doi-asserted-by":"crossref","unstructured":"Twarda-Clapa, A., Olczak, A., Bialkowska, A. M. & Koziolkiewicz, M. Advanced glycation end-products (AGEs): formation, chemistry, classification, receptors, and diseases related to AGEs. Cells 11 (2022).","DOI":"10.3390\/cells11081312"},{"key":"83661_CR34","doi-asserted-by":"publisher","first-page":"e24623","DOI":"10.1371\/journal.pone.0024623","volume":"6","author":"C Han","year":"2011","unstructured":"Han, C., Lu, Y., Wei, Y., Liu, Y. & He, R. D-ribose induces cellular protein glycation and impairs mouse spatial cognition. PLoS One  6, e24623 (2011).","journal-title":"PLoS One"},{"key":"83661_CR35","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1016\/j.bbadis.2019.05.005","volume":"1865","author":"Y Chen","year":"2019","unstructured":"Chen, Y. et al. d-Ribose contributes to the glycation of serum protein. Biochim. Biophys. Acta Mol. Basis Dis. 1865, 2285\u20132292 (2019).","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"83661_CR36","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.kint.2018.03.008","volume":"94","author":"JR Hu","year":"2018","unstructured":"Hu, J. R. et al. Serum metabolites are associated with all-cause mortality in chronic kidney disease. Kidney Int. 94, 381\u2013389 (2018).","journal-title":"Kidney Int."},{"key":"83661_CR37","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1007\/s00439-013-1302-7","volume":"132","author":"A Blaeser","year":"2013","unstructured":"Blaeser, A. et al. Mouse models of fukutin-related protein mutations show a wide range of disease phenotypes. Hum. Genet. 132, 923\u2013934 (2013).","journal-title":"Hum. Genet."},{"key":"83661_CR38","doi-asserted-by":"publisher","first-page":"3995","DOI":"10.1093\/hmg\/ddq314","volume":"19","author":"YM Chan","year":"2010","unstructured":"Chan, Y. M. et al. Fukutin-related protein is essential for mouse muscle, brain and eye development and mutation recapitulates the wide clinical spectrums of dystroglycanopathies. Hum. Mol. Genet. 19, 3995\u20134006 (2010).","journal-title":"Hum. Mol. Genet."},{"key":"83661_CR39","doi-asserted-by":"publisher","first-page":"6656","DOI":"10.1021\/ac901536h","volume":"81","author":"AM Evans","year":"2009","unstructured":"Evans, A. M., DeHaven, C. D., Barrett, T., Mitchell, M. & Milgram, E. Integrated, nontargeted ultrahigh performance liquid chromatography\/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. Anal. Chem. 81, 6656\u20136667 (2009).","journal-title":"Anal. Chem."},{"key":"83661_CR40","doi-asserted-by":"publisher","first-page":"9440","DOI":"10.1073\/pnas.1530509100","volume":"100","author":"JD Storey","year":"2003","unstructured":"Storey, J. D. & Tibshirani, R. Statistical significance for genomewide studies. Proc. Natl. Acad. Sci. USA  100, 9440\u20139445 (2003).","journal-title":"Proc. Natl. Acad. Sci. U S A"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-83661-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-83661-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-83661-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T15:06:37Z","timestamp":1736348797000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-83661-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,8]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["83661"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-83661-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,8]]},"assertion":[{"value":"3 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1329"}}